NLS Pharmaceutics AG (NLSP)
NASDAQ: NLSP · Real-Time Price · USD
0.129
+0.006 (4.87%)
At close: Sep 11, 2024, 4:00 PM
0.125
-0.004 (-3.18%)
After-hours: Sep 11, 2024, 6:08 PM EDT
NLS Pharmaceutics AG Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for NLSP.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for NLSP is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Apr '23 | May '23 | Jun '23 | Jul '23 | Aug '23 | Sep '23 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 14, 2023 |
Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $4 | Hold → Strong Buy | Upgrades | $4 | +2,998.37% | Dec 8, 2022 |
Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 8, 2022 |
Laidlaw & Co. | Laidlaw & Co. | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +4,547.56% | Sep 6, 2022 |
Brookline Capital | Brookline Capital | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +9,195.12% | Mar 12, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.04
from -0.32
EPS Next Year
-0.46
from -0.04
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | n/a | n/a |
Avg | n/a | n/a |
Low | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | -0.04 | -0.47 |
Avg | -0.04 | -0.46 |
Low | -0.04 | -0.44 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.